Alnylam Starts Phase I Study of siRNA Liver Cancer Drug

The study will enroll patients with advanced liver cancers who are refractory to the standard of care, the company said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories